Compositions rich in omega-3 fatty acids with a low content in phytanic acid
The current invention refers to the procedure to obtain compositions rich in omega 3 fatty acids with content in phytanic acid below 90 μg per gram of oil. The current invention also refers to the obtaining of compositions rich in DHA with a content in phytanic acid below 90 μg per gram of oil, more specifically between 650-950 mg/g, that is, between 65% and 95% of DHA in weight and values of PhA below 90 μg, preferably below 5 μg per gram of the oil forming the composition. The compositions obtained are used in the field of food supplements, nutritional products and pharmaceutical products due to their prophylactic action and therapeutic effect.
1. A composition comprising omega 3 fatty acids in a range of 65% to 99% by weight and a content in (phytanic acid) PhA below 90 μg/g.
2. The composition according to claim 1 , wherein the PhA content is below 5 μg/g.
3. The composition according to claim 1 , wherein the range of omega 3 fatty acids is of 75% to 99% by weight.
4. The composition according to claim 3 , wherein the range of omega 3 fatty acids is of 90-99% by weight.
5. The composition according to claim 1 , wherein the omega 3 fatty acids comprise DHA in a range between 65% and 95% by weight.
6. The composition according to claim 5 , wherein the range of DHA is of 75% to 95% by weight.
7. The composition according to claim 6 , wherein the range of DHA is of 80-95% by weight.
8. The composition according to claim 1 , wherein the omega 3 fatty acids additionally include EPA in a range of 5 to 35% by weight.
9. The composition according to claim 2 , wherein the content of DHA is of 80, 65% by weight, the content of EPA is of 13, 38% by weight and the total weight of fatty acids in the mentioned composition is 91, 75% by weight.
10. The composition according to claim 1 , additionally comprising excipients and/or adjuvants intended for pharmaceutical and alimentary use.
11. A nutritional supplement which comprises the composition according to claim 1 and a carrier in the form of a drink, soft or hard gels, aqueous emulsion or powder.
12. A food product which comprises the composition according to claim 1 and a food in the form of a drink, soft or hard gels, aqueous emulsion or powder.
13. A pharmaceutical composition which comprises a composition according to claim 1 , and a pharmaceutical diluent or carrier.
14. A method for the treatment of allergic conditions in the eye, eye surface and/or dry eye, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 , wherein the condition treated are selected from the group consisting of blepharitis, blepharoconjunctivitis, conjunctivitis, keratitis, dry keratoconjunctivitis.
15. A method for the treatment of glaucoma and macular degeneration diseases non associated with genetic dystrophies comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 , wherein the macular degeneration diseases are associated to age.
16. A method for the treatment of hereditary retina dystrophies non retinitis pigmentosa, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 , wherein the hereditary retina dystrophy non retinitis pigmentos treated is selected from the group consisting of Stargardt disease, Leber's congenital amaurosis, Xlinked, Choroideremia, X-linked retinoschisis, Goldman-Favre viteoretinal dystrophy, Wagner's vitreoretinal dystrophy, Stickler's syndrome, Familial Pars Planitis, cystoid macular oedema and Irving-Gass syndrome.
17. A method for the treatment of Retinitis Pigmentosa, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
18. A method for the treatment of multiple sclerosis comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
19. A method for the treatment of nephropaties and patients having undergone renal transplants, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 , wherein the nephropaty treated is selected from the group consisting of nephropathy by IgA, and renal insufficiency associated with malign hypertension and Lupus nephritis.
20. A method for reducing Apoprotein levels, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
21. A method for the treatment of androgenic alopecia, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
22. A method for the treatment of ulcerative colitis, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
23. A method for the treatment of infections caused by Pseudomonas aeruginosa or plasmodiun falciparum , comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
24. A method for the treatment of a deficit or DHA or common nutritional DHA deficiency, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .
25. A method to improve physiological conditions increasing the visual acuity, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1 .